세계 차세대 시퀀싱 시장 규모는 2023년 219억 달러로 평가되었고 예측 기간 동안 복합 연간 성장률(CAGR) 19.3%를 나타낼 전망이며 2028년에는 529억 달러 규모로 성장할 것으로 예측됩니다.
암에 대한 임상적 용도를 위한 차세대 시퀀싱 시장 규모는 2023년 112억 달러에서 복합 연간 성장률(CAGR) 21.6%를 나타낼 전망이며 2028년에는 296억 달러 규모로 성장할 것으로 예측됩니다. 또한 암 이외의 임상 용도를 위한 차세대 시퀀싱 시장 규모는 2023년 107억 달러에서 성장을 지속하여 복합 연간 성장률(CAGR) 16.8%를 나타낼 전망입니다. 2028년에는 233억 달러 가까이에 달할 것으로 예측되고 있습니다.
본 보고서에서는 세계 임상 용도를 위한 차세대 시퀀싱 시장을 조사했으며, 시장 개요, 기술 배경, 임상 NGS에 대한 대처와 신기술, 시장 영향요인 분석, 시장 규모 추이와 예측, 각종 구분, 지역별 상세 분석, 기술 및 특허 동향, ESG 전망, 경쟁 구도, 주요 기업 프로파일 등을 정리했습니다.
목차
제1장 서론
제2장 요약 및 하이라이트
제3장 개요
- 액체 생검 및 조직 생검
- 임상용도용 NGS 시장
- 임상용도용 NGS의 촉진요인
- 주요 동향
- 업계
제4장 기술 배경
- DNA의 중요성
- 유전적 변이와 분석
- 유전자 분석 기술
- 임상용도의 시퀀싱
- 시퀀싱 기술
- DNA 시퀀싱의 역사
- Sanger 시퀀싱 기술
- NGS 플랫폼
- 쇼트 리드 플랫폼
- 링 리드 플랫폼
- 인포매틱스 기술
- 베이스콜링
- 참조 시퀀싱에 매핑
- 변형 분석
- AI 기술
- 임상용 시퀀싱 기술의 과제
제5장 임상 NGS에 대한 대처와 신기술
- R&D의 대처와 프로그램
- 1 Million Genomes
- ACTT(Access to Treatment and Testing)
- ACGP(Access to Comprehensive Genomic Profiling Coalition)
- Africa Pathogen Genomics Initiative
- Blood Profiling Atlas
- Cancer-ID
- Cancer Moon Shots Program
- China Precision Medicine Initiative
- ClinGen
- CTC Trap Consortium
- diaRNAgnosis Project
- Early Cancer Detection Consortium
- EpiFemCare
- France Genomic Medicine Plan
- Friends of Cancer Research Project
- Genomic Medicine Sweden
- HCA-Organoid
- Human Cell Atlas
- Human Immunomics Initiative
- Immunomonitor Consortium
- Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy Program
- Intervene
- Liquid Biopsies and Imaging for Improved Cancer Care
- Liquid Biopsy-Based Malignant Tumor Early Screening Technology Research and Development Project
- Liver Cancer Early Screening Comprehensive Prevention and Control Project
- Lung Cancer Genomic Screening Project for Individualized Medicine in Asia
- Million Veteran Program
- Medical Genome Initiative
- MedSeq
- Precision Medicine Initiative
- Prompt
- QuIP Project
- SPHERES
- Target ALS Diagnosis Initiative
- TopMed
- Treehouse Childhood Cancer Initiative
- Very Rare Cancer Consortium
- Worldwide Innovative Networking(WIN) Consortium
- Single-Cell Research
- Cambridge Single-Cell Analysis Core Facility
- Harvard Medical School Single-Cell Core
- Mayo Medical Genome Facility
- National Center for Single-Cell Biology
- Next-Generation Single-Cell Analysis Program
- Single-Cell Analysis Core
- UC San Francisco Single-Cell Analysis Center
- The Wistar Institute of Anatomy and Biology
- Population Sequencing Projects
제6장 NGS의 임상적 용도
- 암에의 응용
- 정밀의료
- 액체 생검의 바이오 마커
- 멘델성 질환에 응용
- 리프로덕티브 헬스에의 응용
- 비침습적 산전 검사
- 신생아 스크리닝
- 미생물학과 감염증에의 응용
- 복잡한 장애에의 응용
제7장 임상 NGS 산업
- 시퀀싱 기기
- 기업
- 3세대 시퀀싱
- 시퀀싱 인포매틱스
- 타겟 농축 및 증폭
- CTC 캡처& 검출
- 액체 생검 분석
- 액체 생검에 의한 암 스크리닝/조기 발견
- 건강을 중시한 DTC 유전자 검사: 2개 시장 모델
- DTC 임상 건강 유전자 검사
- 비침습적 산전 검사(NIPT)
8장 ESG 배포
- ESG: 소개
- NGS의 지속가능성
- 사례 연구
- BCC에 의한 견해
제9장 인수와 전략적 제휴
제10장 임상 NGS 시장
- 시장 역학
- 시장 성장 촉진요인
- COVID-19가 임상 NGS 시장에 미치는 영향
- 임상 NGS 시장 : 질병 카테고리별
- 임상 NGS 시장 : 검사의 복잡성별
- 임상 NGS 시장 : 검사 목적별
- 종양학에서 임상 NGS 시장
- 시장 : 종양의 적응증별
- 종양의 NGS 시장 : 검사 목적별
- 종양의 NGS 시장 : 검사의 복잡성별
- 심장병의 임상 NGS 시장
- 심장병에 있어서의 NGS 시장 : 검사 목적별
- 심장병에 있어서의 NGS 시장 : 검사의 복잡도별
- 멘델성 질환에 있어서의 임상 NGS 시장
- 멘델성 질환에 있어서의 임상 NGS 시장 : 검사의 복잡도별
- 대사/면역질환에서 임상 NGS 시장
- 대사/면역질환에 있어서의 NGS 시장 : 검사 목적별
- 대사/면역질환에 있어서의 NGS 시장 : 검사의 복잡도별
- 신경내과의 임상 NGS 시장
- 신경내과의 NGS 시장 : 검사 목적별
- 신경내과의 NGS 시장 : 검사의 복잡성별
- Reproductive Health에서 임상 NGS 시장
- Reproductive Healt : 테스트 용도별
- Reproductive Health의 NGS 시장 : 검사 목적별
- Reproductive Health의 NGS 시장 : 검사 복잡성별
- 미생물 및 감염증에서 임상 NGS 시장
- 미생물 및 감염증에 있어서의 NGS 시장 : 검사 목적별
- 미생물 및 감염증에 있어서의 NGS 시장 : 검사의 복잡도별
- 이식에 있어서의 임상 NGS 시장
- 이식에 있어서의 NGS 시장 :장기별
- 이식에 있어서의 NGS 시장 : 검사 목적별
- 이식에 있어서의 NGS 시장 : 검사의 복잡도별
- 임상 NGS 시장 : 지역별
- 종양에 있어서의 NGS 세계 시장 :지역별
- 리프로덕티브 헬스에 있어서의 NGS 세계 시장 :지역별
- 이식에 있어서의 NGS 세계 시장 :지역별
제11장 특허 리뷰
- 순환 종양 세포에 관한 특허
- 엑소좀에 관한 특허
- 무세포 DNA에 관한 특허
- 바이오마커 관련 특허
- 암 진단에서 AI 사용에 관한 특허 : 고려 사항
- 액체 생검의 특허 소송
제12장 기업 프로파일
- 경쟁 구도
- 톱 5사
- AGILENT TECHNOLOGIES INC.
- BGI GENOMICS CO. LTD
- ILLUMINA INC.
- QIAGEN
- THERMO FISHER SCIENTIFIC INC.
- Other Companies
- ACCURAGEN HOLDINGS
- ADAPTIVE BIOTECHNOLOGIES
- ALCEN
- AMBRY GENETICS
- AMOY DIAGNOSTICS CO. LTD.
- ANGLE PLC
- APOSTLE SCIENCES
- ARCEDI BIOTECH APS
- ARMONICA TECHNOLOGIES INC.
- ARUP LABORATORIES
- ASURAGEN INC.
- BAYLOR GENETICS
- BECTON, DICKINSON AND CO.
- BERRY GENOMICS BEIJING
- BIOCAPTIVA LTD.
- BIOCEPT INC.
- BIODESIX
- BIOFLUIDICA
- BIOLIDICS LTD
- BIOLOGICAL DYNAMICS
- BIOMODAL
- BIONANO GENOMICS
- BIO-RAD LABORATORIES INC.
- BIO-TECHNE
- C2I GENOMICS
- CAPIO BIOSCIENCES
- CAREDX INC.
- CARIS LIFE SCIENCE
- CEGAT GMBH
- CELL MICROSYSTEMS
- CENTRILLION GENOMICS TECHNOLOGIES
- CLARET BIOSCIENCE
- CLEAR NOTE HEALTH
- CLINICAL GENOMICS TECHNOLOGIES
- CYCLOMICS
- CYGNUS BIOSCIENCES CO. LTD.
- DANAHER
- DANTE LABS
- DATAR CANCER GENETICS LTD.
- DELFI DIAGNOSTICS
- DIACARTA
- DIAGNOLOGIX LLC
- DIAGNOMICS INC.
- DIAMIR BIO
- DNALYTICS
- DNANEXUS INC.
- EARLYDIAGNOSTICS
- EONE-DIAGNOMICS GENOME CENTER CO. LTD.
- EPIC SCIENCES
- EPIGENOMICS AG
- EUROFINS GENOMICS
- EVERLY HEALTH INC.
- EXACT SCIENCES CORP.
- EXOPERT
- EXOSOMICS INC.
- EZLIFE BIO
- FABRIC GENOMICS INC.
- F. HOFFMANN-LA ROCHE LTD
- FLUXION BIOSCIENCES INC.
- FREENOME HOLDINGS INC.
- FULGENT GENETICS
- FULL GENOMES CORP.
- GENE BY GENE LTD.
- GENEDX LLC
- GENESEQ BIOSCIENCES
- GENOMONCOLOGY LLC
- GENOSABER
- GRAIL INC.
- GUARDANT HEALTH
- HELIO GENOMICS
- HELIX INC.
- HTG MOLECULAR DIAGNOSTICS INC.
- IMAGIA CANEXIA HEALTH
- INCELLDX INC.
- INEX INNOVATE PRIVATE LTD
- INOVIQ
- INTERPACE BIOSCIENCES INC.
- INVITAE CORP.
- INVIVOSCRIBE INC.
- JABREHOO MED TECH CO. LTD.
- JBS SCIENCE
- JUMPCODE GENOMICS INC.
- KONINKLIJKE PHILIPS NV
- LABGENOMICS CO. LTD.
- LABORATORY CORPORATION OF AMERICA HOLDINGS
- LIQUID BIOPSY LABS
- LUCENCE HEALTH INC.
- LUNGLIFE AI INC.
- MACROGEN INC.
- MAPMYGENOME
- MDXHEALTH INC.
- MEDGENOME
- MEDICOVER GENETICS
- MENARINI SILICON BIOSYSTEMS SPA
- MERCK KGAA
- MICAREO RARE CELL DIAGNOSTICS
- MICRONOMA INC.
- MIR SCIENTIFIC
- MUTANTDX
- MYRIAD GENETICS INC.
- NANOSTRING TECHNOLOGIES INC.
- NATERA INC.
- NEBULA GENOMICS
- NEOGENOMICS LABORATORIES
- NEW ENGLAND BIOLABS
- NEW HORIZON HEALTH LTD.
- NOVIGENIX SA
- NOVOGENE CO. LTD.
- NRICHDX INC.
- NUPROBE INC.
- NX PRENATAL INC.
- ONCIMMUNE HOLDINGS PLC
- ONCOCYTE CORP.
- ONCODNA
- OPKO HEALTH
- ORCHID
- OXFORD NANOPORE TECHNOLOGIES LTD.
- PACIFIC BIOSCIENCES OF CALIFORNIA INC.
- PANGAEA ONCOLOGY
- PERSONAL GENOME DIAGNOSTICS INC.
- PERSONALIS INC.
- PHASE SCIENTIFIC
- PIERIANDX
- PREDICINE
- PRENETICS GROUP
- QCDX LLC
- QUANTAPORE
- QUANTGENE INC.
- QUANTUMDX
- QUEST DIAGNOSTICS
- RARECELLS INC.
- RAVGEN
- REAL TIME GENOMICS
- RESOLUTION BIOSCIENCE INC.
- SAGA DIAGNOSTICS AB
- SANO GENETICS
- SCREENCELL
- SEEKIN INC.
- SEQUENCING.COM
- SEVEN BRIDGES GENOMICS INC.
- SINGLE TECHNOLOGIES
- SMARTCATCH
- STAGEZERO LIFE SCIENCES. LTD.
- STRAND
- STRATA ONCOLOGY
- SYAPSE INC.
- SYSMEX INOSTICS GMBH
- TAKARA BIO INC.
- TELEXOS GMBH
- TWINSTRAND BIOSCIENCES INC.
- TWIST BIOSCIENCE
- UNCHAINED LABS
- UNIVERSAL DX
- VELA DIAGNOSTICS
- VERACYTE
- VOLITIONRX
- VORTEX BIOSCIENCES
- YOURGENE HEALTH
- YIKON GENOMICS CO. LTD.
BJH
Highlights:
The global market for clinical applications of next-generation sequencing is estimated to increase from $21.9 billion in 2023 to reach $52.9 billion by 2028, at a compound annual growth rate (CAGR) of 19.3% from 2023 through 2028.
The global market for clinical applications of next-generation sequencing for cancer is estimated to increase from $11.2 billion in 2023 to reach $29.6 billion by 2028, at a CAGR of 21.6% from 2023 through 2028.
The global market for clinical applications of next-generation sequencing for non-cancerous diseases is estimated to increase from $10.7 billion in 2023 to reach nearly $23.3 billion by 2028, at a CAGR of 16.8% from 2023 through 2028.
Report Scope:
The scope of the report includes clinical NGS technologies, applications, industries, initiatives, patents, and companies. The markets for NGS-based diagnostics are given for the years 2020, 2021, 2022, 2023 and 2028.
This report reviews the main sequencing technologies and explains why genetic variation is important in clinical testing. It then discusses some of the significant research initiatives that impact clinical NGS applications. Liquid biopsy formats are discussed. The main market driving forces are also discussed.
The report examines the markets by test complexity, clinical indication and test purpose. Test complexity refers to the plex level (i.e., the number of genetic markers that can be analyzed within a sample) and coverage (e.g., the extent to which the genome is covered) of the test. Examining the market by test complexity provides valuable insight into which products (e.g., sample preparation, NGS instrument, informatics, etc.) will be in demand in the future.
The report provides market data and forecasts for NGS diagnostics by specific applications, including those for oncology, cardiovascular diseases, clinical microbiology/infectious diseases, Mendelian disorders, metabolic/immune disorders, neurological disorders, reproductive health, and transplant medicine.
Specific geographic markets are discussed, namely North America, Europe, Asia-Pacific, and the Rest of the World.
Industry sectors analyzed include DNA sequencing instruments; long-read sequencing; sequencing informatics; target enrichment; CTC capture and detection; liquid biopsy; cancer screening/early detection; direct-to-consumer testing; and noninvasive prenatal testing.
More than 100 companies in the clinical NGS industry are profiled in this report.
BCC Research also provides a summary of the recent, primary industry acquisitions and strategic alliances, including key alliance trends.
Report Includes:
- 41 data tables and 237 additional tables
- An overview of the global market for emerging clinical applications of next-generation sequencing
- Analysis of global market trends, featuring historical revenue data for 2020 to 2022, estimates for 2023, as well as forecasts for 2028, including projections of compound annual growth rates (CAGRs) through 2028
- Evaluation of the current market size and revenue growth prospects, accompanied by a market share analysis by disease indication, test complexity, test purpose, application and geographic region
- Discussion of market opportunities for clinical NGS products, clinical applications, industry structure, regulatory scenarios and use of NGS-based diagnostics and technologies
- Coverage of genome mapping programs, technological advances and innovations in NGS platforms, and the Ion Torrent Genexus System from Thermo Fisher Scientific and the Magnis NGS Prep System lfrom Agilent Technologies Inc
- Description of NGS-oriented tests such as non-invasive prenatal testing (NIPT) and pre-implantation genetic testing (PGT), and a discussion of their advantages
- Market share analysis of the key companies and a look at their proprietary technologies, strategic alliances and other key market strategies, plus a patent analysis
- Profiles of the leading players, including Illumina Inc., Thermo Fisher Scientific Inc., QIAGEN, Agilent Technologies Inc., and BGI Genomics
Table of Contents
Chapter 1 Introduction
- Study Goals and Objectives
- Reasons for Doing This Study
- Scope of Report
- Information Sources
- Methodology
- What's New in This Report?
- Geographic Breakdown
- Segmentation Breakdown
Chapter 2 Summary and Highlights
- Market Outlook
- Market Summary
Chapter 3 Overview
- Introduction
- Liquid and Tissue Biopsy
- Clinical NGS Market
- Growth Drivers of Clinical NGS
- Key Trends
- Industry
Chapter 4 Technology Background
- Importance of DNA
- Genetic Variation and Analysis
- Genetic Analysis Technologies
- Sequencing in Clinical Applications
- Sequencing Technologies
- History of DNA Sequencing
- Sanger Sequencing Technology
- NGS Platforms
- Short-Read Platforms
- Long-Read Platforms
- Informatics Technologies
- Base Calling
- Mapping to a Reference Sequence
- Variant Analysis
- Artificial Intelligence Technologies
- Clinical Sequencing Technology Challenges
Chapter 5 Clinical NGS Initiatives and Emerging Technologies
- R&D Initiatives and Programs
- 1+ Million Genomes
- Access to Treatment and Testing (ACTT)
- Access to Comprehensive Genomic Profiling Coalition (ACGP)
- Africa Pathogen Genomics Initiative
- Blood Profiling Atlas
- Cancer-ID
- Cancer Moon Shots Program
- China Precision Medicine Initiative
- ClinGen
- CTC Trap Consortium
- diaRNAgnosis Project
- Early Cancer Detection Consortium
- EpiFemCare
- France Genomic Medicine Plan
- Friends of Cancer Research Project
- Genomic Medicine Sweden
- HCA-Organoid
- Human Cell Atlas
- Human Immunomics Initiative
- Immunomonitor Consortium
- Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy Program
- Intervene
- Liquid Biopsies and Imaging for Improved Cancer Care
- Liquid Biopsy-Based Malignant Tumor Early Screening Technology Research and Development Project
- Liver Cancer Early Screening Comprehensive Prevention and Control Project
- Lung Cancer Genomic Screening Project for Individualized Medicine in Asia
- Million Veteran Program
- Medical Genome Initiative
- MedSeq
- Precision Medicine Initiative
- Prompt
- QuIP Project
- SPHERES
- Target ALS Diagnosis Initiative
- TopMed
- Treehouse Childhood Cancer Initiative
- Very Rare Cancer Consortium
- Worldwide Innovative Networking (WIN) Consortium
- Single-Cell Research
- Cambridge Single-Cell Analysis Core Facility
- Harvard Medical School Single-Cell Core
- Mayo Medical Genome Facility
- National Center for Single-Cell Biology
- Next-Generation Single-Cell Analysis Program
- Single-Cell Analysis Core
- UC San Francisco Single-Cell Analysis Center
- The Wistar Institute of Anatomy and Biology
- Population Sequencing Projects
Chapter 6 Clinical NGS Applications
- Introduction
- Cancer Applications
- Precision Medicine
- Liquid Biopsy Biomarkers
- Mendelian Disorders Applications
- Reproductive Health Applications
- Noninvasive Prenatal Testing
- Newborn Screening
- Microbiology and Infectious Disease Applications
- Complex Disorders Applications
Chapter 7 Clinical NGS Industry
- Sequencing Instrument Industry
- Companies
- Third-Generation Sequencing Industry
- Sequencing Informatics Industry
- Target Enrichment and Amplification Industry
- CTC Capture and Detection Industry
- Liquid Biopsy Assay Industry
- Liquid Biopsy Cancer Screening/Early Detection Industry
- Health-Focused DTC Genetic Testing Industry: Two Market Models
- DTC Clinical Health Genetic Testing Industry
- Noninvasive Prenatal Testing (NIPT) Industry
Chapter 8 ESG Development
- Introduction to ESG
- The Sustainability of NGS in Industry
- Case Study
- BCC Research Viewpoint
Chapter 9 Acquisitions and Strategic Alliances
- Acquisitions
- Strategic Alliances
- Key Trends
Chapter 10 Clinical NGS Markets
- Market Dynamics
- Market Drivers
- Impact of COVID-19 on the Clinical NGS Markets
- Clinical NGS Market by Disease Category
- Clinical NGS Market by Test Complexity
- Clinical NGS Market by Purpose of Test
- Clinical NGS Market in Oncology
- Market by Indication in Oncology
- NGS Market in Oncology by Purpose of Test
- NGS Market in Oncology by Test Complexity
- Clinical NGS Market in Cardiology
- NGS Market in Cardiology by Purpose of Test
- NGS Market in Cardiology by Test Complexity
- Clinical NGS Market in Mendelian Disorders
- NGS Market in Mendelian Disorders by Test Complexity
- Clinical NGS Market in Metabolic/Immune Disorders
- NGS Market in Metabolic/Immune Disorders by Purpose of Test
- NGS Market in Metabolic/Immune Disorders by Test Complexity
- Clinical NGS Market in Neurology
- NGS Market in Neurology by Test Purpose
- NGS Market in Neurology by Test Complexity
- Clinical NGS Market in Reproductive Health
- Reproductive Health Market by Test Application
- NGS Market in Reproductive Health by Purpose of Test
- NGS Market in Reproductive Health by Test Complexity
- Clinical NGS Market in Microbiology and Infectious Diseases
- NGS Market in Microbiology and Infectious Diseases by Purpose of Test
- NGS Market in Microbiology and Infectious Diseases by Test Complexity
- Clinical NGS Market in Transplantation
- NGS Market in Transplantation by Organ Type
- NGS Market in Transplantation by Purpose of Test
- NGS Market in Transplantation by Test Complexity
- Clinical NGS Market by Region
- Global Market for NGS in Oncology by Region
- Global Market for NGS in Reproductive Health by Region
- Global Market for NGS in Transplantation by Region
Chapter 11 Patent Review
- Patents on Circulating Tumor Cells
- Patents on Exosomes
- Patents on Cell-Free DNA
- Patents Related to Biomarkers
- Patent Considerations for the Use of Artificial Intelligence in Cancer Diagnostics
- Liquid Biopsy Patent Litigation
Chapter 12 Company Profiles
- Competitive Landscape
- Top 5 Companies
- AGILENT TECHNOLOGIES INC.
- BGI GENOMICS CO. LTD
- ILLUMINA INC.
- QIAGEN
- THERMO FISHER SCIENTIFIC INC.
- Other Companies
- ACCURAGEN HOLDINGS
- ADAPTIVE BIOTECHNOLOGIES
- ALCEN
- AMBRY GENETICS
- AMOY DIAGNOSTICS CO. LTD.
- ANGLE PLC
- APOSTLE SCIENCES
- ARCEDI BIOTECH APS
- ARMONICA TECHNOLOGIES INC.
- ARUP LABORATORIES
- ASURAGEN INC.
- BAYLOR GENETICS
- BECTON, DICKINSON AND CO.
- BERRY GENOMICS BEIJING
- BIOCAPTIVA LTD.
- BIOCEPT INC.
- BIODESIX
- BIOFLUIDICA
- BIOLIDICS LTD
- BIOLOGICAL DYNAMICS
- BIOMODAL
- BIONANO GENOMICS
- BIO-RAD LABORATORIES INC.
- BIO-TECHNE
- C2I GENOMICS
- CAPIO BIOSCIENCES
- CAREDX INC.
- CARIS LIFE SCIENCE
- CEGAT GMBH
- CELL MICROSYSTEMS
- CENTRILLION GENOMICS TECHNOLOGIES
- CLARET BIOSCIENCE
- CLEAR NOTE HEALTH
- CLINICAL GENOMICS TECHNOLOGIES
- CYCLOMICS
- CYGNUS BIOSCIENCES CO. LTD.
- DANAHER
- DANTE LABS
- DATAR CANCER GENETICS LTD.
- DELFI DIAGNOSTICS
- DIACARTA
- DIAGNOLOGIX LLC
- DIAGNOMICS INC.
- DIAMIR BIO
- DNALYTICS
- DNANEXUS INC.
- EARLYDIAGNOSTICS
- EONE-DIAGNOMICS GENOME CENTER CO. LTD.
- EPIC SCIENCES
- EPIGENOMICS AG
- EUROFINS GENOMICS
- EVERLY HEALTH INC.
- EXACT SCIENCES CORP.
- EXOPERT
- EXOSOMICS INC.
- EZLIFE BIO
- FABRIC GENOMICS INC.
- F. HOFFMANN-LA ROCHE LTD
- FLUXION BIOSCIENCES INC.
- FREENOME HOLDINGS INC.
- FULGENT GENETICS
- FULL GENOMES CORP.
- GENE BY GENE LTD.
- GENEDX LLC
- GENESEQ BIOSCIENCES
- GENOMONCOLOGY LLC
- GENOSABER
- GRAIL INC.
- GUARDANT HEALTH
- HELIO GENOMICS
- HELIX INC.
- HTG MOLECULAR DIAGNOSTICS INC.
- IMAGIA CANEXIA HEALTH
- INCELLDX INC.
- INEX INNOVATE PRIVATE LTD
- INOVIQ
- INTERPACE BIOSCIENCES INC.
- INVITAE CORP.
- INVIVOSCRIBE INC.
- JABREHOO MED TECH CO. LTD.
- JBS SCIENCE
- JUMPCODE GENOMICS INC.
- KONINKLIJKE PHILIPS N.V.
- LABGENOMICS CO. LTD.
- LABORATORY CORPORATION OF AMERICA HOLDINGS
- LIQUID BIOPSY LABS
- LUCENCE HEALTH INC.
- LUNGLIFE AI INC.
- MACROGEN INC.
- MAPMYGENOME
- MDXHEALTH INC.
- MEDGENOME
- MEDICOVER GENETICS
- MENARINI SILICON BIOSYSTEMS SPA
- MERCK KGAA
- MICAREO RARE CELL DIAGNOSTICS
- MICRONOMA INC.
- MIR SCIENTIFIC
- MUTANTDX
- MYRIAD GENETICS INC.
- NANOSTRING TECHNOLOGIES INC.
- NATERA INC.
- NEBULA GENOMICS
- NEOGENOMICS LABORATORIES
- NEW ENGLAND BIOLABS
- NEW HORIZON HEALTH LTD.
- NOVIGENIX SA
- NOVOGENE CO. LTD.
- NRICHDX INC.
- NUPROBE INC.
- NX PRENATAL INC.
- ONCIMMUNE HOLDINGS PLC
- ONCOCYTE CORP.
- ONCODNA
- OPKO HEALTH
- ORCHID
- OXFORD NANOPORE TECHNOLOGIES LTD.
- PACIFIC BIOSCIENCES OF CALIFORNIA INC.
- PANGAEA ONCOLOGY
- PERSONAL GENOME DIAGNOSTICS INC.
- PERSONALIS INC.
- PHASE SCIENTIFIC
- PIERIANDX
- PREDICINE
- PRENETICS GROUP
- QCDX LLC
- QUANTAPORE
- QUANTGENE INC.
- QUANTUMDX
- QUEST DIAGNOSTICS
- RARECELLS INC.
- RAVGEN
- REAL TIME GENOMICS
- RESOLUTION BIOSCIENCE INC.
- SAGA DIAGNOSTICS AB
- SANO GENETICS
- SCREENCELL
- SEEKIN INC.
- SEQUENCING.COM
- SEVEN BRIDGES GENOMICS INC.
- SINGLE TECHNOLOGIES
- SMARTCATCH
- STAGEZERO LIFE SCIENCES. LTD.
- STRAND
- STRATA ONCOLOGY
- SYAPSE INC.
- SYSMEX INOSTICS GMBH
- TAKARA BIO INC.
- TELEXOS GMBH
- TWINSTRAND BIOSCIENCES INC.
- TWIST BIOSCIENCE
- UNCHAINED LABS
- UNIVERSAL DX
- VELA DIAGNOSTICS
- VERACYTE
- VOLITIONRX
- VORTEX BIOSCIENCES
- YOURGENE HEALTH
- YIKON GENOMICS CO. LTD.
